Abstract |
We treated elderly patients (65-69 years) who had aggressive lymphoma with the CyclOBEAP regimen, and we studied the safety and efficacy of this treatment. The CyclOBEAP regimen was administered over a total period of 12 weeks. Doxorubicin 40 mg/m(2) was given every 2 weeks in combination with either cyclophosphamide 800 mg/m(2) or etoposide 70 mg/m(2) qd x 3. During the alternate weeks, non-myelosuppressive vincristine 1.0 mg/m(2) was given either with bleomycin 10 mg/m(2) or alone. Prednisolone 40 mg/m(2) was administered daily for three 14-day periods during weeks 1-2, 5-6 and 9-10. There were 51 eligible patients. A complete response was achieved in 42 patients (82%). The 5-year overall survival (OS) rate was 60.6% and progression-free survival (PFS) rate was 51.8%. WHO grade 4 neutropenia was observed in 32 patients and thrombocytopenia in 8 patients. We showed that the CyclOBEAP regimen can be safely used in the treatment of aggressive lymphoma in elderly patients and it achieved a high rate of remission.
|
Authors | Nozomi Niitsu, Masataka Okamoto, Mika Kohori, Sadao Aoki, Ikuo Miura, Masami Hirano |
Journal | Hematological oncology
(Hematol Oncol)
Vol. 24
Issue 4
Pg. 220-6
(Dec 2006)
ISSN: 0278-0232 [Print] England |
PMID | 16958147
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Bleomycin
- Vincristine
- Etoposide
- Doxorubicin
- Cyclophosphamide
- Prednisolone
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Bleomycin
(administration & dosage, adverse effects)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Disease-Free Survival
- Doxorubicin
(administration & dosage, adverse effects)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy, mortality)
- Male
- Neutropenia
(chemically induced)
- Prednisolone
(administration & dosage, adverse effects)
- Remission Induction
- Survival Rate
- Thrombocytopenia
(chemically induced)
- Time Factors
- Treatment Outcome
- Vincristine
(administration & dosage, adverse effects)
|